10-Q: Cryoport Q3 Revenue Jumps 15.4% Amid Strategic Divestiture

Cryoport, Inc. reported a 15.4% increase in total revenue for the third quarter of 2025, driven by strong demand in life sciences services and products, alongside a significant gain from the divestiture of its CRYOPDP business.

Summary

• Total revenue from continuing operations increased by 15.4% to $44.2 million for the three months ended September 30, 2025, compared to $38.3 million in the same period in 2024.
• For the nine months ended September 30, 2025, total revenue from continuing operations increased by 13.4% to $130.7 million, up from $115.3 million in the prior year period.
• Life Sciences Services revenue grew by 15.9% to $24.3 million in Q3 2025, with BioLogistics Solutions revenue increasing by 14.6% and BioStorage/BioServices revenue by 21.5%.
• Life Sciences Products revenue increased by 14.9% to $20.0 million in Q3 2025, driven by demand in EMEA, APAC, and Animal Health customers in the Americas.
• Commercial Cell & Gene Therapy revenue within BioLogistics Solutions increased by 21.7% to $7.4 million in Q3 2025, compared to $6.1 million in Q3 2024.
• The company supported 745 clinical trials globally as of September 30, 2025, including 83 in Phase 3, representing an increase of 54 clinical trials from 691 at September 30, 2024.
• Net income for the nine months ended September 30, 2025, was $89.9 million, a significant improvement from a net loss of $(96.1) million in the prior year, primarily due to a $115.4 million gain from the divestiture of the CRYOPDP business.
• Cash and cash equivalents increased significantly to $255.8 million at September 30, 2025, from $34.1 million at December 31, 2024, largely due to the proceeds from the CRYOPDP sale.
• The 2025 Senior Notes, with a principal amount of $14.3 million, were repaid upon maturity on June 1, 2025.
• The company repurchased 1,111,614 shares of its common stock for an aggregate purchase price of $8.0 million during the nine months ended September 30, 2025, under its repurchase programs, with approximately $65.9 million of authorization remaining.

Sentiment

Score: 7

Explanation: The company demonstrated strong revenue growth in its core continuing operations and significantly improved its net income year-to-date due to a strategic divestiture, boosting cash reserves. Liquidity is robust. While there was a net loss from continuing operations in Q3, the overall strategic direction and growth in supported clinical trials are positive indicators. Risks related to economic conditions and foreign exchange are noted but not presented as immediate crises.

Positives

• Strong revenue growth in continuing operations, with a 15.4% increase in Q3 2025 and 13.4% YTD 2025.
• Significant growth in Commercial Cell & Gene Therapy revenue, increasing by 21.7% in Q3 2025 for BioLogistics Solutions.
• Increased number of clinical trials supported, reaching 745 (83 in Phase 3) as of September 30, 2025, indicating a robust pipeline for future commercialization.
• Improved gross margin for continuing operations, rising to 48.2% in Q3 2025 from 45.5% in Q3 2024.
• Substantial increase in cash and cash equivalents to $255.8 million, significantly bolstered by the CRYOPDP divestiture proceeds.
• Net income of $89.9 million for the nine months ended September 30, 2025, representing a major turnaround from a net loss in the prior year, driven by the strategic divestiture.
• Reduction in Selling, General and Administrative (SG&A) expenses by 7.6% for the nine months ended September 30, 2025, reflecting effective cost management.
• Repayment of $14.3 million in 2025 Senior Notes, reducing debt obligations.

Negatives

• Net loss from continuing operations of $(6.7) million in Q3 2025, compared to net income of $3.9 million in Q3 2024.
• Overall net loss of $(6.9) million in Q3 2025, a significant decrease from net income of $0.8 million in Q3 2024.
• Investment income decreased by $2.0 million for the nine months ended September 30, 2025, compared to the prior year.
• Other income (expense), net decreased by $1.0 million for the nine months ended September 30, 2025, compared to the prior year.
• Provision for income taxes increased by $0.2 million for the nine months ended September 30, 2025.
• Net cash used in operating activities was $(9.5) million for the nine months ended September 30, 2025.

Risks

• Effects of changing economic and geopolitical conditions.
• Supply chain constraints.
• Inflationary pressures impacting costs of labor, material, transportation, and pricing from third-party manufacturers, potentially affecting financial performance if not offset by price increases and productivity gains.
• Foreign currency exchange fluctuations, which could result in material gains or losses on intercompany balances and impact revenue, with potential declines of $1.3 million, $2.5 million, and $5.0 million for 5%, 10%, and 20% adverse changes to foreign exchange on foreign-denominated cash, respectively.
• Variations in the company's cash flow.
• Market acceptance risks for products and services.
• Continued U.S. federal government shutdown causing delays in customer purchases or federal agency oversight, which could materially and adversely affect results of operations, cash flows, and liquidity.
• Effects of tariffs and other trade restrictions.
• Technical development risks.
• Risks related to the CRYOPDP Transaction, including the ability to retain and hire key personnel.
• Risk that any disruption resulting from the CRYOPDP Transaction may adversely affect businesses and business relationships, including with employees and suppliers.
• The need to obtain additional capital to fund operations and potential acquisitions until sustained profitable operations are achieved, with no assurance that additional capital will be available when required or upon terms acceptable to the company.

Future Outlook

The company expects to continue incurring significant expenses and operating losses in the near term as it invests in new supply chain initiatives, geographic expansion, and technology to support anticipated growth. Management believes that current cash, cash equivalents, short-term investments, and projected cash flows will be sufficient to meet operational and capital requirements for at least the next twelve months. The divestiture of CRYOPDP and strategic partnership with DHL are expected to enhance the company's ability to develop its business, particularly in the EMEA and APAC regions, and provide differentiated, high-value services aligned with long-term growth.

Management Comments

• "We are 'Enabling the Future of Medicine'."
• "The divestiture and strategic partnership with DHL are expected to enhance the Company's ability to develop its business, particularly in the EMEA and APAC regions, and to provide differentiated and high-value services aligned with the Company's long-term growth strategy."
• "We believe regenerative medicine advanced therapies that successfully advance through the clinical trial process and receive commercial approval from the respective regulatory agencies will represent opportunities to become significant revenue drivers for us as the majority of them will require comprehensive temperature-controlled supply chain support and other services at commercial scale."
• "We expect that most will select us as their critical supply chain solution partner as a result of our work in connection with their respective clinical trials and our long track record of innovation and market responsiveness."
• "Our Company continues to lead the way in providing advanced temperature-controlled supply chain solutions designed to support the development of Cell and Gene therapies and our future growth."

Industry Context

Cryoport operates in the rapidly growing life sciences sector, particularly in regenerative medicine and cell and gene therapies, which require specialized temperature-controlled supply chain solutions. The company's focus on supporting clinical trials and commercial launches of these advanced therapies positions it within a high-growth segment. The strategic divestiture of the CRYOPDP specialty courier business and partnership with DHL aim to streamline operations and enhance capabilities in key international markets (EMEA and APAC), aligning with broader industry trends towards specialized, high-value logistics for sensitive biological materials. The continued increase in supported clinical trials, especially in Phase 3, indicates a strong pipeline in the biopharmaceutical industry for future commercialization.

Legal Proceedings

• The company may become a party to product litigation in the normal course of business.
• Currently not aware of any legal proceedings or claims that are believed to have a material adverse effect on business, operating results, or cash flows.

Stakeholder Impact

• Shareholders: Potential impact from share repurchase programs, net income/loss, and future growth from strategic initiatives.
• Employees: Risks related to retaining and hiring key personnel following the CRYOPDP divestiture.
• Suppliers: Risks related to business relationships following the CRYOPDP divestiture.
• Customers: Potential delays in purchasing products and services due to U.S. federal government shutdown.

Next Steps

• Continue investments in new supply chain initiatives, geographic expansion, and technology to support anticipated growth.
• Evaluate the full effects of Public Law 119-21 (tax reform provisions) on the estimated annual tax rate and cash tax provision.
• Potentially obtain additional capital to fund operations and potential acquisitions if needed, though current liquidity is deemed sufficient for the next twelve months.
• Continue repurchasing common stock and/or convertible senior notes under the authorized programs.

Key Dates

Recommendation

The company shows strong revenue growth in its core life sciences segments and has significantly improved its overall financial position year-to-date due to a strategic divestiture, boosting cash reserves. The increase in supported clinical trials, especially in Phase 3, indicates a robust pipeline for future commercialization. However, the net loss from continuing operations in the most recent quarter and ongoing investments suggest that profitability in core operations is still developing. While the long-term outlook for specialized temperature-controlled logistics in regenerative medicine is positive, the near-term operational losses and external risks (inflation, government shutdown, foreign exchange) warrant a cautious "hold" stance. Investors should monitor the company's ability to translate clinical trial support into sustained commercial revenue and achieve profitability in its continuing operations.

Keywords

Cryoport, Life Sciences, Temperature-controlled supply chain, Regenerative medicine, Cell and Gene Therapy, Biologistics, Biostorage, Bioservices, Cryogenic systems, SEC filing, 10-Q, Financial results, Divestiture, DHL, Clinical trials, MVE Biological Solutions, Share repurchase